Infliximab

Introduction Overview

Generic Name

Infliximab

Brand Name

Remicade

Dosage Form

Intravenous infusion

Drug Class

Antirheumatics; TNF alpha inhibitors

Pharmacokinetics

Absorption:
Remicade (infliximab) is administered exclusively via intravenous infusion, which results in immediate bioavailability as the drug enters systemic circulation directly. Unlike orally administered drugs, it bypasses gastrointestinal absorption and first-pass metabolism, ensuring 100% bioavailability. This direct route avoids the issues of variable absorption seen with other administration methods but requires healthcare setting administration under supervision due to potential infusion reactions.

Distribution:
Infliximab exhibits a volume of distribution approximating plasma volume, reflective of its nature as a large chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). It circulates primarily in the vascular and extracellular fluid compartments. Because it is a large protein molecule, it does not readily cross the blood-brain barrier or penetrate intracellular compartments. The binding to soluble and transmembrane TNF-α influences its tissue distribution and pharmacodynamics. In clinical studies, infliximab’s distribution profile corresponds with its mechanism to neutralize TNF-α in inflamed tissues.

Metabolism:
As a monoclonal antibody, infliximab is metabolized by proteolytic enzymes throughout the reticuloendothelial system. This catabolic pathway involves degradation into small peptides and amino acids, which are then recycled by the body. It is not metabolized by hepatic cytochrome P450 enzymes, thus minimizing interactions with drugs metabolized by these pathways. The metabolism of infliximab is largely non-saturable and not significantly affected by hepatic or renal impairment since it depends on proteolytic degradation common to endogenous immunoglobulins.

Elimination:
Elimination of infliximab occurs primarily via nonspecific proteolytic catabolism. The average terminal half-life ranges from approximately 7 to 12 days, influenced by factors such as anti-drug antibody formation, disease state, and concomitant immunosuppressive therapy. Clearance is reduced when combined with immunosuppressive agents such as methotrexate, which lowers immunogenicity and antibody development. Due to its prolonged half-life, infliximab dosing is typically scheduled every 6 to 8 weeks following the induction phase. The elimination kinetics are consistent with monoclonal antibody clearance profiles and are not impacted by renal or hepatic dysfunction significantly.

Dosage Forms

Available Dosage Forms:
- Single-Dose Vial: 100 mg infliximab powder for intravenous infusion (reference product Remicade and biosimilars Avsola, Inflectra, Renflexis)
- Autoinjector: 120 mg/mL solution (Zymfentra)
- Pre-Filled Syringe: 120 mg/mL solution (Zymfentra)

Dosages for Adults and Adolescents:
- Rheumatoid Arthritis: Induction doses typically start at 3 mg/kg by IV infusion, followed by subsequent doses at 2 and 6 weeks after the initial dose, and maintenance dosing every 8 weeks.
- Crohn's Disease and Ulcerative Colitis: Induction dosing at 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dosing every 8 weeks.
- Ankylosing Spondylitis and Psoriatic Arthritis: Similar dosing to rheumatoid arthritis with 5 mg/kg every 6 to 8 weeks.
- Plaque Psoriasis: Dosing starts at 5 mg/kg, with maintenance infusions every 8 weeks.
- Pediatric Use: Approved in children 6 years and older for Crohn’s disease and ulcerative colitis at 5 mg/kg dosing similar to adults.

Specific Patient Populations:
- Patients with latent tuberculosis or active infection must be screened and treated appropriately before initiation.
- Use caution in patients with heart failure, infections, liver disease, or a history of malignancy.
- Pediatric dosing recommendations for Crohn’s disease and ulcerative colitis begin at age 6.
- Adjust dosing and monitor carefully in elderly patients due to increased infection risk.
- No dosage adjustment for renal or hepatic impairment is typically required due to the metabolism and elimination profile of monoclonal antibodies.
- Concomitant immunosuppressants may affect dosing intervals and immunogenicity.

Mechanism Of Action

Remicade (infliximab) is a chimeric monoclonal antibody designed to specifically target and neutralize tumor necrosis factor-alpha (TNF-α), a cytokine centrally involved in systemic inflammation and immune regulation. It binds with high affinity to soluble and transmembrane forms of TNF-α, thereby preventing its interaction with TNF receptors on cell surfaces and blocking the downstream signaling pathways responsible for the inflammatory cascade.

At the molecular level, infliximab binding neutralizes TNF-α’s ability to induce the expression of adhesion molecules, cytokines, and enzymes that drive leukocyte recruitment, activation, and tissue destruction. This inhibition disrupts the chronic inflammatory cycle seen in autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Furthermore, infliximab-bound transmembrane TNF-α can induce apoptosis of activated immune cells, decreasing the number of pathogenic cells contributing to disease activity.

Cellularly, Remicade modulates immune cell function by inhibiting macrophage and T-cell activation, thereby decreasing pro-inflammatory cytokine production and leukocyte infiltration into affected tissues. This leads to reduced synovial inflammation, decreased joint damage in arthritis, and mucosal healing in inflammatory bowel diseases. Clinical implications include improved symptom control, decreased disease progression, and enhanced quality of life in treated patients.

Comparatively, infliximab shares its TNF-alpha blocking properties with other biologics such as adalimumab and etanercept; however, as a chimeric antibody, it may differ in immunogenicity profile and pharmacokinetics. Multiple clinical trials have demonstrated the efficacy and safety of infliximab in various autoimmune conditions, establishing it as a cornerstone biological therapy. Ongoing research explores its combinational effects with immunomodulators and emerging biosimilar products to optimize therapeutic strategies.

Pharmacological Actions

Neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory responses.
Inhibits the binding of TNF-α to its receptors, thereby blocking downstream pro-inflammatory signaling.
Induces apoptosis of activated inflammatory cells expressing transmembrane TNF-α.
Suppresses macrophage and T-cell activation, decreasing cytokine production.
Decreases leukocyte migration and infiltration into inflamed tissues.
Reduces synovial inflammation and joint destruction in rheumatoid arthritis.
Promotes mucosal healing in inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
Modulates immune responses to attenuate chronic autoimmune inflammation.
Does not activate complement-mediated cytotoxicity, reducing nonspecific tissue damage.
Acts as a disease-modifying agent by slowing progression of tissue damage.
Synergizes with immunosuppressive agents to reduce immunogenicity and improve efficacy.
Restores homeostasis in immune signaling pathways disrupted during chronic inflammation.
Possesses a long half-life allowing for sustained therapeutic effect with intermittent dosing.

Therapeutic Or Clinical Uses

Treatment of moderate to severe rheumatoid arthritis, especially in patients inadequately responding to methotrexate.
Management of active psoriatic arthritis to reduce signs and symptoms and inhibit structural damage.
Therapy of ankylosing spondylitis to reduce disease activity and improve functional status.
Control of severe or disabling plaque psoriasis in adults unresponsive to other systemic therapies.
Induction and maintenance treatment of moderate to severe Crohn’s disease in adults and children ages 6 years and older.
Induction and maintenance treatment of moderate to severe ulcerative colitis in adults and pediatric patients 6 years and older.
Utilized in autoimmune conditions characterized by elevated TNF-α levels and chronic inflammation.
Used for patients who have failed or are intolerant to conventional therapies.
Off-label use in certain inflammatory and autoimmune disorders as determined by clinical judgment.
Adjunctive therapy combined with other disease-modifying antirheumatic drugs (DMARDs) to improve therapeutic outcomes.
Employed in decreasing corticosteroid dependence in inflammatory bowel disease patients.
Facilitates mucosal healing and remission maintenance in inflammatory bowel diseases.
Can be used as part of step-up therapy for psoriasis and inflammatory arthropathies.
Reduces systemic manifestations and improves health-related quality of life in targeted patient populations.

Side Or Adverse Effects

Infusion-related reactions including dizziness, nausea, headache, chills, fever, itching, rash, and hypotension during or shortly after infusion.
Increased susceptibility to infections, including serious and potentially fatal bacterial, fungal, viral, and opportunistic infections such as tuberculosis.
Development of anti-drug antibodies leading to infusion reactions and reduced clinical efficacy.
Risk of new or worsening congestive heart failure, with symptoms such as dyspnea, edema, and weight gain.
Lupus-like syndrome presenting with joint pain, rash, chest discomfort, and fatigue during treatment.
Hepatotoxicity manifesting as abnormal liver function tests, jaundice, and hepatic inflammation.
Hematologic abnormalities including pancytopenia, anemia, leukopenia, and thrombocytopenia.
Neurologic adverse events such as seizures, demyelinating disorders, numbness, tingling, and vision changes.
Rare but serious malignancies including lymphoma, hepatosplenic T-cell lymphoma especially in younger patients, and skin cancers.
Delayed hypersensitivity reactions occurring up to 12 days post-infusion with rash, fever, arthralgia, and swelling.
Autoimmune phenomena including the development of autoantibodies and vasculitis.
Common mild adverse effects like upper respiratory tract infections, sinusitis, cough, abdominal pain, and headaches.
Potential allergic reactions including anaphylaxis, urticaria, and angioedema.
Reactivation of latent hepatitis B infection leading to severe liver complications.
Potential worsening or new onset psoriasis in treated patients.

Precautions

Screen patients for latent or active tuberculosis prior to initiation and monitor regularly during therapy.
Avoid use in patients with known hypersensitivity to infliximab or murine proteins.
Use cautiously in patients with congestive heart failure; monitor for worsening symptoms during treatment.
Regularly monitor for signs of infection; withhold therapy if serious infections occur.
Assess hepatitis B virus status before and during treatment due to risk of viral reactivation.
Monitor liver enzymes periodically as infliximab may induce hepatotoxicity.
Evaluate neurological status as infliximab may trigger or exacerbate demyelinating disorders.
Exercise caution in patients with immunosuppression or a history of recurrent infections.
Avoid live vaccines during treatment and for at least 6 months after discontinuation of infliximab.
Ensure pediatric patients are up to date on immunizations before starting therapy.
Use during pregnancy only if potential benefits outweigh risks; inform pediatricians of in utero exposure.
Do not breastfeed during treatment due to unknown effects on the infant.
Monitor for infusion reactions and have appropriate medical support available during infusions.
Adjust concomitant immunosuppressive therapy to minimize immunogenicity and adverse effects.
Inform patients regarding potential risks including malignancy, infection, and allergic reactions.

Warnings

Contraindicated in patients with allergic reactions to infliximab or murine proteins.
Avoid concomitant use with anakinra or abatacept due to increased risk of infection and immunosuppression.
Significant risk of serious and sometimes fatal infections including tuberculosis, fungal infections, and opportunistic pathogens.
May increase risk of malignancies, including rare fatal hepatosplenic T-cell lymphoma, especially in young males with Crohn’s disease or ulcerative colitis.
Not recommended for use in children under 6 years old due to safety concerns.
Live vaccines should not be administered to patients during or shortly after infliximab therapy due to risk of severe infection.
Potential for infusion reactions, some life-threatening, necessitating slow infusion rates and monitoring.
May cause worsening or new onset of congestive heart failure; caution advised in patients with cardiac disease.
Risk of demyelinating disease including multiple sclerosis and Guillain-Barré syndrome.
Potential for developing autoimmunity including lupus-like syndrome and vasculitis.
Pregnant women should inform their healthcare providers and pediatricians about exposure due to effects on vaccination schedules.
Breastfeeding is contraindicated during infliximab treatment.
Patients should be monitored for signs of hematologic abnormalities such as pancytopenia.
Immunogenicity may reduce therapeutic effectiveness and increase adverse events.
Patients with history of malignancy require thorough risk assessment before initiating therapy.

Contraindication

Known hypersensitivity to infliximab or murine-derived proteins.
Concomitant treatment with other biologic TNF inhibitors or immunomodulators like anakinra or abatacept.
Active, severe infections including sepsis, tuberculosis, and opportunistic infections.
Treatment in patients with moderate to severe congestive heart failure (NYHA class III/IV).
Use in children younger than 6 years of age due to insufficient safety data.
History of hypersensitivity or anaphylaxis to previous infliximab administration.
Receiving live vaccines during treatment and for an extended period afterward.
Severe hepatic impairment or significant active liver disease without appropriate monitoring.
Known malignancy contraindicates initiation without thorough risk-benefit analysis.
Pregnancy unless benefits outweigh risks, with close monitoring of mother and infant.
Concurrent use with other biologics that modulate the immune system increasing risk of toxicity.
Patients with demyelinating neurological disorders unless benefits outweigh risks.
Patients with hematologic abnormalities such as severe leukopenia or thrombocytopenia.
Use in immunocompromised patients contraindicated without close infectious disease monitoring.
Uncontrolled chronic infections contraindicate use until resolution.

Drug Interactions

Concurrent use with other biologic immunomodulators like anakinra and abatacept increases risk of serious infections and is contraindicated.
Potential additive immunosuppressive effects when combined with other TNF inhibitors such as adalimumab, certolizumab, etanercept, golimumab.
Use with methotrexate and other conventional DMARDs may alter infliximab clearance and reduce immunogenicity.
Concomitant use with tocilizumab (an IL-6 receptor antagonist) may amplify immunosuppression and infection risk.
Immunosuppressive therapy may mask signs of infection during concomitant use.
Live vaccines are contraindicated during and after infliximab treatment due to risk of systemic infection.
Potential interaction with corticosteroids affecting immune response and infection susceptibility.
May modify effects of vaccines administered prior to therapy.
No significant interactions with cytochrome P450-metabolized drugs due to monoclonal antibody metabolism.
Caution when used with anticoagulants or drugs increasing bleeding risk due to potential immunological effects.
Antibiotics and antivirals may be required when infections occur during therapy.
Herbal supplements affecting immune function may interact unpredictably, requiring clinical monitoring.
Drug levels and effect may be altered by antibody formation; monitoring recommended when combining with immunomodulators.
Concomitant use of other anti-inflammatory agents requires clinical vigilance for additive adverse effects.
Patient’s full medication profile must be reviewed to avoid polypharmacy-related adverse effects.

Preparations Of The Drug

Remicade (infliximab) supplied as lyophilized powder in single-dose vials containing 100 mg infliximab for reconstitution and intravenous infusion.
Zymfentra (infliximab-dyyb) available as 120 mg/mL solution in autoinjectors and pre-filled syringes, used as a biosimilar reference biologic.
Avsola (infliximab-axxq) biosimilar available as 100 mg single-dose vial for IV infusion, offering an alternative to Remicade.
Inflectra (infliximab-dyyb) biosimilar preparation identical in strength and administration route, also supplied in 100 mg vials.
Renflexis (infliximab-abda) biosimilar product formulated as 100 mg single-dose vial for infusion.
Ixifi (infliximab-qbtx), a biosimilar previously available as 100 mg vial but currently discontinued.
All preparations are intended for intravenous administration under medical supervision with standardized reconstitution and infusion protocols.
Biosimilars require prescription by name to ensure appropriate dispensing and substitution policies.
Preparation involves reconstitution with sterile water and dilution according to package insert before slow intravenous infusion.
Storage conditions generally require refrigeration and protection from light, with strict adherence to stability guidelines.
Vials and autoinjectors are single-use and should be handled aseptically to prevent contamination.
Preparation and administration details are provided in professional prescribing information and must be assured in clinical settings.
Availability of multiple biosimilars allows cost-effective treatment options while maintaining clinical efficacy and safety.
Patient education on drug administration and monitoring is essential due to complex biological nature of the medication.
Pharmacy regulations mandate precise handling, labeling, and tracking due to specialty drug status.